BR112018070847A2 - terapias combinadas para tratamento de câncer compreendendo um derivado de bacterioclorofila - Google Patents

terapias combinadas para tratamento de câncer compreendendo um derivado de bacterioclorofila

Info

Publication number
BR112018070847A2
BR112018070847A2 BR112018070847A BR112018070847A BR112018070847A2 BR 112018070847 A2 BR112018070847 A2 BR 112018070847A2 BR 112018070847 A BR112018070847 A BR 112018070847A BR 112018070847 A BR112018070847 A BR 112018070847A BR 112018070847 A2 BR112018070847 A2 BR 112018070847A2
Authority
BR
Brazil
Prior art keywords
treating cancer
bacteriochlorophyll derivative
bchl
combined therapies
agent
Prior art date
Application number
BR112018070847A
Other languages
English (en)
Portuguese (pt)
Inventor
Scherz Avigdor
Preise Dina
Coleman Jonathan
Kim Kwanghee
Agemy Liiach
Hamri Rachel
Salomon Yoram
Original Assignee
Memorial Sloan Kettering Cancer Center
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Yeda Res & Dev filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112018070847A2 publication Critical patent/BR112018070847A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112018070847A 2016-04-10 2017-04-10 terapias combinadas para tratamento de câncer compreendendo um derivado de bacterioclorofila BR112018070847A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Publications (1)

Publication Number Publication Date
BR112018070847A2 true BR112018070847A2 (pt) 2019-02-05

Family

ID=58794130

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018070847A BR112018070847A2 (pt) 2016-04-10 2017-04-10 terapias combinadas para tratamento de câncer compreendendo um derivado de bacterioclorofila

Country Status (14)

Country Link
US (2) US11278555B2 (cg-RX-API-DMAC7.html)
EP (1) EP3442582A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019510807A (cg-RX-API-DMAC7.html)
KR (2) KR20190008206A (cg-RX-API-DMAC7.html)
CN (2) CN118304400A (cg-RX-API-DMAC7.html)
AU (2) AU2017250732B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018070847A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020067A1 (cg-RX-API-DMAC7.html)
IL (1) IL262191B2 (cg-RX-API-DMAC7.html)
MX (2) MX390751B (cg-RX-API-DMAC7.html)
RU (2) RU2021110230A (cg-RX-API-DMAC7.html)
SG (1) SG11201808849TA (cg-RX-API-DMAC7.html)
WO (1) WO2017179053A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201807187B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
CN106458190B (zh) 2014-05-30 2019-12-06 戴科知识产权控股有限责任公司 具有喷射器、气动控制阀和可选择的吸气器的真空创建系统
WO2019116376A1 (en) * 2017-12-17 2019-06-20 Yeda Research And Development Co. Ltd. Cop9 signalosome (csn) complex modulators and uses thereof
WO2022149934A1 (ko) * 2021-01-08 2022-07-14 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201172B1 (pl) 1998-12-09 2009-03-31 Yeda Res & Dev Pd-Bakteriofeoforbid, sposób jego wytwarzania, kompozycja farmaceutyczna zawierająca go i jego zastosowanie
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
AU2009305893B2 (en) 2008-10-23 2014-03-27 Steba Biotech S.A. RGD-containing peptidomimetics and uses thereof
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
TWI442945B (zh) * 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Also Published As

Publication number Publication date
MX2022003190A (es) 2022-04-11
EP3442582A1 (en) 2019-02-20
RU2747258C2 (ru) 2021-04-29
US20190125769A1 (en) 2019-05-02
MX390751B (es) 2025-03-21
AU2017250732A1 (en) 2018-11-15
JP2022031823A (ja) 2022-02-22
SG11201808849TA (en) 2018-11-29
AU2017250732B2 (en) 2022-11-10
IL262191B2 (en) 2025-01-01
KR20190008206A (ko) 2019-01-23
IL262191A (en) 2018-11-29
IL262191B1 (en) 2024-09-01
CA3020067A1 (en) 2017-10-19
AU2023200591A1 (en) 2023-03-09
US20220202838A1 (en) 2022-06-30
JP2019510807A (ja) 2019-04-18
CN109862918A (zh) 2019-06-07
WO2017179053A1 (en) 2017-10-19
ZA201807187B (en) 2020-01-29
CN118304400A (zh) 2024-07-09
RU2018139523A (ru) 2020-05-15
RU2021110230A (ru) 2021-05-26
US11278555B2 (en) 2022-03-22
RU2018139523A3 (cg-RX-API-DMAC7.html) 2020-07-07
MX2018012392A (es) 2019-08-21
KR20220139445A (ko) 2022-10-14

Similar Documents

Publication Publication Date Title
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
MX391720B (es) Terapia combinada para tratar cáncer.
MX390878B (es) Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
WO2016025635A3 (en) Combination therapy for treating cancer
MX2022008868A (es) Tratamiento del cancer con tg02.
BR112014031088A8 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
MX392408B (es) Tratamiento de cáncer gástrico usando terapias de combinación que comprenden irinotecán liposómico oxaliplatino, 5-fluoruracilo (y leucovorina).
BR112018006817A2 (pt) método de tratamento do câncer
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX373231B (es) Agente anticancerigeno.
WO2016043874A3 (en) Combination therapy for treating cancer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
MX2018016332A (es) Quimioterapias de combinacion.
BR112018002530A2 (pt) combinações e usos e tratamentos destas
MX2020001727A (es) Terapia de combinacion.
MX386249B (es) Terapia tusc2 para usarse en el tratamiento de cáncer.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]